FINAL PROGRAMfid.belgradesymposium2018.rs/sites/default/files/fid... · 2018-12-11 · Branislava...

Post on 12-Jan-2020

2 views 0 download

transcript

CEDA/FID Scientific Update Symposium

DIABETES CONTROL AND PREVENTIONOF VASCULAR COMPLICATIONS:ACHIEVEMENTS AND DILEMMAS

FINAL PROGRAM

December 14-15, 2018 Hotel Crowne Plaza, Belgrade, Serbia

Committees

Naučni odbor/Scientific Committee

Predsednik/presidentJelena Parojčić

Članovi/membersDanica AgbabaMilica Atanacković KrstonošićErem BilensoyBranka BrzakovićSilva DobrićSvetlana IbrićVladimir JakovljevićVesna Spasojević KalimanovskaNada KovačevićTereza KowalskaGordana LeposavićVesna MatovićBranislava MiljkovićMiroslav SavićSvetlana StojkovSlađana ŠobajićLjiljana TasićRadmila Veličković RadovanovićAndreas Zimmer

3

INFO

FRID

AYSA

TURD

AYN

OTE

S

General information

4

SATURD

AYFRID

AYIN

FON

OTES

Committees

Steering Committee

ChairProf Nebojsa M. Lalic

MembersProf Luis Gardete Correia (Portugal)Prof Janusz Gumprecht (Poland)Assoc Prof Erifylli Hatziagelaki (Greece)Prof Christian Herder (Germany)Prof Andrej Janez (Slovenia)Prof Peter Kempler (Hungary)Prof Ilze Konrade (Latvia)Prof Roger Lehmann (Switzerland)Prof Tatjana Milenkovic (Macedonia)Prof Asimina Mitrakou (Greece)Prof Michael Roden (Austria)Prof Jan Skrha (Czeck Republic)Prof Lea Smircic Duvnjak (Croatia)Prof Thomas Stulnig (Austria)Prof Tsvetalina Tankova (Bulgaria)Prof Ioan Veresiu (Romania)Prof Raimund Weitgasser (Austria)

Local co-organizersFaculty of Medicine, University of BelgradeDiabetes Society of Serbia

Local Organizing Committee

PresidentNebojsa M. Lalic

MembersAleksandra JoticKatarina LalicLjiljana LukicTanja MilicicMarija MacesicNatasa OgnjanovicLjiljana PopovicNatasa RajkovicJelena Stanarcic Gajovic Milica StojiljkovicLjubica Stosic

Executive organizerSMART TRAVEL PCO

5

INFO

FRID

AYSA

TURD

AYN

OTE

S

General Information

Meeting venueThe scientific program of the Symposium will take place in the Hall A and B at mezzanine level of the Hotel Crowne Plaza.

RegistrationThe pre-registered participants are kindly asked to take their meeting materials at the Secretariat desk.The Secretariat desk will be situated in front of the halls. The desk should be contacted for all the information regarding the Symposium.For the registered participants an opportunity of becoming member of CEDA/FID or prolonging the membership for one year is available, supported by Novo Nordisk educational grant. Please, contact the Secretariat desk and fill in the form that will be available at the desk.

Opening hoursFriday, December 14th 11.00-19.00Saturday, December 15th 07.30-13.00

Important information to speakersSpeakers are kindly asked to comply with the schedule of their presentations.Lectures are scheduled to last 20 minutes.The Power Point presentations are to be delivered at the Speakers ready room at least 30 minutes before the start of the session.For all additional information, please contact the Secretariat of the Symposium.

LanguageThe official language of the meeting is English.

LunchLunch is served for all participants of the Symposium in front of Hall A and B.

Certificate of attendanceCertificate of attendance will be available at the end of the Symposium at Secretariat desk.

Accommodation, social program, dinner, tours and hospitality informationFor all the information regarding accommodation, social program, dinner, tours and hospitality, please refer to the Secretariat desk and where our executive organizer SMART TRAVEL PCO will be pleased to assist you.

Important addressesLocal Organizing CommitteeProfessor Dr Nebojsa M. Lalic, PresidentFaculty of Medicine University of BelgradeClinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of SerbiaDr Subotica 1311000 Belgrade, SerbiaPhone: +381 11 36 39 781e-mail: nebojsa.m.lalic@gmail.com

Local executive organizerSMART TRAVEL PCONjegoševa 72а11000 Belgrade, SerbiaPhone: +381 11 770 21 84, 770 25 22e-mail: smarttravelpco4@smarttravelpco4.rs www.smarttravelpco4.rs

6

SATURD

AYFRID

AYIN

FON

OTES

Acknowledgment

The CEDA/FID Scientific Update Symposium is supported by Wordwide Diabetes

and by an unrestricted grant of Novo Nordisk

7

INFO

FRID

AYSA

TURD

AYN

OTE

S

Final program

9

INFO

FRID

AYSA

TURD

AYN

OTE

S

Friday, December 14, 2018 HALL A

12.00-13.00 LUNCH

13.00-13.15 WELCOME ADDRESSES

13.15-15.15 WORLDWIDE DIABETES SYMPOSIUM TYPE 2 DIABETES: GLUCOSE CONTROL AND BEYOND

13.15 Welcome, introductions and objectivesC. Mathieu (Leuven, Belgium)

13.25 Obesity and diabetes: the lethal linkM. Bluher (Leipzig, Germany)

13.45 GLP-1 receptor agonist therapy: it is only the beginningJ. Meier (Bochum, Germany)

14.05 Cardiovascular outcomes trials: how they have changed the diabetes worldL. Czupryniak (Warsaw, Poland)

14.30 ADA/EASD Consensus: towards individualized glucose lowering therapyC. Mathieu (Leuven, Belgium)

14.55 Panel discussion All faculty

15.10 Wrap upC. Mathieu (Leuven, Belgium)

15.15-15.30 COFFEE BREAK

10

SATURD

AYFRID

AYIN

FON

OTES

Friday, December 14, 2018 HALL A/B

15.30-17.00 SESSION 1 (HALL A)Chairpersons: M. Roden (Dusseldorf, Germany), T. Stulnig (Vienna, Austria)

15.30 Obesity, diabetes and cardiovascular diseaseT. Stulnig (Vienna, Austria)

15.50 Fatty liver and vascular diabetes complicationsM. Roden (Dusseldorf, Germany)

16.10 Glucose variability and macrovascular complicationsR. Weitgasser (Salzburg, Austria)

16.30 Atherogenesis in diabetes: the role of low-grade inflammationC. Herder (Dusseldorf, Germany)

16.50 Discussion

15.30-17.00 SESSION 2 (HALL B)Chairpersons: I. Veresiu (Cluj Napoca, Romania), P. Kempler (Budapest, Hungary)

15.30 SGLT-2 inhibitors in type 1 diabetes: relevance for arterial functionA. Janez (Ljubljana, Slovenia)

15.50 Autonomic neuropathy: impact on carbohydrate metabolism and therapeutic challenges P. Kempler (Budapest, Hungary)

16.10 Peripheral vascular disease and diabetic foot: relationship to CVDI. Veresiu (Cluj Napoca, Romania)

16.30 Discussion

17.00-17.30 COFFEE BREAK

11

INFO

FRID

AYSA

TURD

AYN

OTE

S

Friday, December 14, 2018 HALL A/B

17.30-19.00 SESSION 3 (HALL A)Chairpersons: C. Mathieu (Leuven, Belgium), R. Lehmann (Zurich, Switzerland)

17.30 Type 1 vs type 2 diabetes: new approaches in insulin and adjunct therapiesC. Mathieu (Leuven, Belgium)

17.50 Cardioprotective effects in CVOTs: possible mechanismsN.M. Lalic (Belgrade, Serbia)

18.10 Hypoglycemia and cardiovascular complicationsA. Mitrakou (Athens, Greece)

18.30 Islet and pancreas transplantation: effect on chronic complicationsR. Lehmann (Zurich, Switzerland)

18.50 Discussion

17.30-19.00 SESSION 4 (HALL B)Chairpersons: E. Hatziagelaki (Athens, Greece), L. Smircic-Duvnjak (Zagreb, Croatia)

17.30 Metformin and cardiovascular protection revisitedE. Hatziagelaki (Athens, Greece)

17.50 Incretins therapy and cardiovascular risk factorsL. Smircic-Duvnjak (Zagreb, Croatia)

18.10 Long-acting vs short-acting GLP-1RA: differences in cardioprotective effectC. Guja (Bucharest, Romania)

18.30 Glucose and sodium regulation by the kidney: relevance for metabolic control and vascular complicationsT. Klupa (Krakow, Poland)

18.50 Discussion

20.00-23.00 OUTSIDE DINNER

12

SATURD

AYFRID

AYIN

FON

OTES

Saturday, December 15, 2018 HALL A

08.00-09.00 CEDA/FID BOARD MEETING

09.00-10.00 SESSION 5 (HALL A) NEW APPROACHES TO CARDIOVASCULAR PROTECTION IN DIABETES: HOW TO ACHIEVE IN CEDA COUNTRIES (PANEL DISCUSSION)Moderator: M. Roden (Dusseldorf, Germany)

Panelists (short 5 min introductions)

New ADA/EASD consensus: implications for daily practice C. Mathieu (Leuven, Belgium)

Impact of CVOTs and ADA/EASD consensus in clinical practice: experiences from Austria T. Stulnig (Vienna, Austria)

Impact of CVOTs and ADA/EASD consensus in clinical practice: experiences from Serbia N.M. Lalic (Belgrade, Serbia)

How to harmonize the use of the new therapeutic approaches in the CEDA countries?M. Roden (Dusseldorf, Germany)

Discussion

10.00-10.30 COFFEE BREAK

10.30-12.00 SESSION 6 (HALL A)Chairpersons: T. Tankova (Sofia, Bulgaria), I. Konrade (Riga, Latvia)

10.30 Treatment of obesity: relevance for the prevention of CVDT. Tankova (Sofia, Bulgaria)

10.50 Treatment of dyslipidemia in diabetes: new CVOTsK. Lalic (Belgrade, Serbia)

11.10 Treatment of hypertension in diabetes: relevance to vascular complicationsA. Jotic (Belgrade, Serbia)

11.30 Education in diabetes to prevent CVDT. Milenkovic (Skopje, Macedonia)

11.50 Discussion

12.00 CLOSING REMARKS AND LUNCH

13

NO

TES

INFO

FRID

AYSA

TURD

AY

Notes

14

NO

TESSATU

RDAY

FRIDAY

INFO

15

NO

TES

INFO

FRID

AYSA

TURD

AY

16

NO

TESSATU

RDAY

FRIDAY

INFO

17

NO

TES

INFO

FRID

AYSA

TURD

AY

18

NO

TESSATU

RDAY

FRIDAY

INFO

CEDA/FID Scientific Update Symposium

DIABETES CONTROL AND PREVENTIONOF VASCULAR COMPLICATIONS:ACHIEVEMENTS AND DILEMMAS

FINAL PROGRAM

December 14-15, 2018 Hotel Crowne Plaza, Belgrade, Serbia